DEFA14A: Masimo Responds to Politan's Statements on Board Control and Director Nomination

Masimo clarifies its position on settlement negotiations with Politan Capital Management, addressing concerns about board control and the nomination of Chris Chavez.

Summary

• Masimo issued a statement on May 31, 2024, addressing recent claims made by Politan Capital Management regarding settlement talks and the nomination of Chris Chavez to Masimo's board of directors.
• Masimo stated that Politan's compromise proposals would have given Politan control of the Masimo Board without securing the support of a majority of Masimo's stockholders or paying a control premium.
• The company explained that the process of identifying Mr. Chavez was expedited due to Rolf Classon's unexpected resignation three weeks prior.
• Masimo noted that Kiani's prior association with Mr. Chavez was through their service on the Medical Device Manufacturers Association board, from which Mr. Chavez resigned over 12 years ago.
• Masimo has filed a preliminary proxy statement with the SEC for its 2024 Annual Meeting and intends to file and mail a definitive proxy statement to its stockholders.
• Stockholders are encouraged to read the definitive proxy statement and accompanying GOLD proxy card when available, as they will contain important information.

Sentiment

Score: 5

Explanation: The document presents a neutral stance, primarily focused on clarifying information and addressing concerns related to a proxy battle. It lacks strong positive or negative indicators, reflecting a defensive posture.

Positives

• Masimo is actively communicating with its shareholders regarding the ongoing situation with Politan Capital Management.
• The company is providing clarity on the nomination process and addressing concerns about board control.

Negatives

• The dispute with Politan Capital Management suggests potential disagreements on the company's strategic direction.
• The abbreviated process for identifying Mr. Chavez due to Rolf Classon's sudden resignation may raise concerns about the thoroughness of the selection process.

Risks

• Uncertainties regarding future actions that may be taken by Politan in furtherance of its nomination of director candidates for election at the 2024 Annual Meeting.
• The potential cost and management distraction attendant to Politan's nomination of director nominees at the 2024 Annual Meeting.
• Uncertainties regarding a potential separation of Masimo's Consumer Business.

Future Outlook

The document contains forward-looking statements regarding the 2024 Annual Meeting and potential stockholder approval of the Board's nominees, but cautions that actual results could differ materially due to various risk factors.

Management Comments

• Each compromise that Mr. Koffey offered involved Politan controlling a majority of the Masimo Board, without earning the support of a majority of Masimo's stockholders and without paying any control premium.
• The process for identifying Mr. Chavez was abbreviated due to Rolf Classons sudden resignation three weeks ago.
• Mr. Kianis prior acquaintance with Mr. Chavez was in connection with their service on the Medical Device Manufacturers Association board, from which Mr. Chavez resigned more than 12 years ago.

Industry Context

The dispute with Politan Capital Management highlights the increasing activist investor activity in the medical device industry, where companies are facing pressure to improve performance and shareholder value.

Stakeholder Impact

• The outcome of the proxy battle could significantly impact the composition of Masimo's board of directors and, consequently, the company's strategic direction.
• The uncertainty surrounding the situation may affect shareholder confidence and the company's stock price.

Next Steps

• Masimo will file and mail a definitive proxy statement to its stockholders.
• Stockholders are encouraged to read the definitive proxy statement and accompanying GOLD proxy card when available.
• The company will hold its 2024 Annual Meeting of Stockholders.

Key Dates

Keywords

Masimo, Politan Capital Management, Proxy Statement, Board of Directors, Annual Meeting, Settlement Negotiations, Director Nomination, Chris Chavez, Kiani, Stockholders